RSLS earnings

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2024, including a corporate update on Thursday, November 14, 2024, after market. Management will host a conference call on Thursday, November 14 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the

IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2024, including a corporate update on Wednesday, August 14, 2024, after market. Management will host a conference call on August 15 at 4:30 pm ET, and will be joined by Krishna K. Gupta, a current Director of Vyome Therapeutics, who will be appointed Chairman of the combined company upon completion of the previously announced merger agreement between the two companies. A live webcast will be available on the "Events and Presenta

Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update. First Quarter 2024 and Subsequent Highlights Ma

IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2024, including a corporate update on Wednesday, May 15, 2024, after market. Management will host a conference call on May 15 at 4:30 pm ET. A live webcast will be available on the "Events and Presentations" section of ReShape's website at: https://ir.reshapelifesciences.com/events-and-presentations. To access the call by phone, please register with the following Registration Link, and dial-in details will be pro

IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2023, including a corporate update on Wednesday, November 8, 2023, after market. Management will host a conference call on November 8 at 5:00 pm ET. A live webcast will be available on the "Events and Presentations" section of ReShape's website at: https://ir.reshapelifesciences.com/events-and-presentations. To access the call by phone, please register with the following Registration Link, and dial-in details will be provid

IRVINE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2023, including a corporate update on Monday, August 7, 2023, after market. Management will host a conference call at 5:00 pm ET the same day and will be joined by a member of ReShape's Scientific Advisory Board, Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of the NYU Langone Weight Management Program and Chief of the Division of Bariatric Surgery. A live webcast will be availab

SAN CLEMENTE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2023, including a corporate update on Monday, May 15, 2023, after market. Management will host a conference call on May 15 at 4:30 pm ET. A live webcast will be available on the "Events and Presentations" section of ReShape's website at: https://ir.reshapelifesciences.com/events-and-presentations. To access the call by phone, please register with the following Registration Link, and dial-in details will be provided. Partici

SAN CLEMENTE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will delay its year ended December 31, 2022 earnings release and conference call, previously scheduled for 8:00 am ET on March 29, 2022. The delay is required to allow the company additional time to complete its year end audited financial information. ReShape Lifesciences will issue a press release announcing a new date and time of the postponed earnings release and conference call upon completion of the year end audited financial information. About ReShape Lifesciences® ReShape Lifescie

SAN CLEMENTE, Calif., March 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the year ended December 31, 2022, including a corporate update, on Wednesday, March 29, 2023, pre-market. Management will host a conference call on March 29 at 8:00 am ET. A live webcast will be available on the "Events and Presentations" section of ReShape's website at: https://ir.reshapelifesciences.com/events-and-presentations. To access the call by phone, please register with the following Registration Link, and dial-in details will be provided. Parti

SAN CLEMENTE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the third quarter ended September 30, 2022 and provided a corporate strategic update. Third Quarter and Subsequent Highlights In August, Paul F. Hickey, a seasoned executive with over 25 years of medical device commercialization experience, was appointed President and Chief Executive Officer.In August, received U.S. Food and Drug Administration (FDA) 510(k) clearance for the disposable Gastro Intestinal Balloon Indicator (GIBI HD™) calibration tube for use in gastr

SAN CLEMENTE, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended September 30, 2022, including a corporate update, on Monday, November 14, 2022, pre-market. Management will host a conference call on November 14 at 8:00 am ET. A live webcast will be available on the "Events and Presentations" section of ReShape's website at: https://ir.reshapelifesciences.com/events-and-presentations. To access the call by phone, please register with the following Registration Link, and dial-in details will be pro

Second Quarter Revenues Increased 19% Sequentially, Indicating DTC Campaign Continues to Drive Demand for Lap-Band® Procedures Conference Call to be Held at 4:30 pm ET Today SAN CLEMENTE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the second quarter ended June 30, 2022 and provided a corporate strategic update. Second Quarter and Subsequent Highlights In July, received U.S. Food and Drug Administration (FDA) 510(k) clearance for the disposable Gastro Intestinal Balloon Indicator (GIBI HD™) calibration tube for

SAN CLEMENTE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the second quarter ended June 30, 2022, including a corporate update, on Monday, August 15, 2022, after-market. Management will host a conference call on August 15 at 4:30 pm ET. A live webcast will be available on the "Events and Presentations" section of ReShape's website at: https://ir.reshapelifesciences.com/events-and-presentations. To access the call by phone, please register with the following Registration Link, and dial-in details will be provi

March 2022 Revenues Exceeded January's and February's, Combined, Indicating DTC Campaign and Other Visibility Activities are Driving Significant Demand for Lap-Band® Procedures Conference Call to be Held at 8:30 am ET Today SAN CLEMENTE, Calif., May 23, 2022 (GLOBE NEWSWIRE) --  ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the first quarter ended March 31, 2022 and provided a corporate strategic update. First Quarter Highlights and Accomplishments Ongoing, direct-to-consumer (DTC) marketing campaign continues to be successful in driving demand, filling surgeons'

SAN CLEMENTE, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the year ended December 31, 2021 and provided a corporate strategic update. 2021 Highlights and Accomplishments Achieved a significant, 20.4% increase in revenue, year-over-yearListed on Nasdaq via a successful merger with Obalon Therapeutics, positioning ReShape as a major leader in the weight loss marketRaised $46 million in cash to execute our business strategyEliminated all debt from the balance sheet including $10.5 million of term debt with an institutional

Full Year Revenue Increased by Approximately 20%, from $11.3 M to $13.6 M $22.8 M in Cash and Cash Equivalents as of December 31, 2021 Company Eliminated All Debt from Balance Sheet Webcast to be Held at 5:30 pm ET on Monday, March 28, 2022 SAN CLEMENTE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the year-ended December 31, 2021, including a corporate update, on Monday, March 28, 2022, after-market. A conference call and webcast will be held at 5:30 pm ET. "2021 was a transformative year for ReShape, punctu

SAN CLEMENTE, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, announced today that it will report its third quarter 2021 financial and operational results on Thursday, November 11, 2021 at 8:30 a.m. ET. Management will post a webinar to discuss ReShape's financial results at 8:45 a.m. ET that same day. The link to the webinar will be available on the Investor Relations page of the ReShape Lifesciences, Inc. website, https://ir.reshapelifesciences.com/. About ReShape Lifesciences Inc. ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions compan